NCST priced at $10USYYORK, Dec 21 (Reuters) - NUCRYST Pharmaceuticals Corp., a wholly owned subsidiary of Westaim Corp. ,on Wednesday priced the initial public offering of 4.5 million shares at $10 per share, below a forecast of $12 to $14.
The company disclosed the IPO price in an amended IPO document filed with the U.S. Securities and Exchange Commission.
The 4.5 million share deal is worth $5 million. The company had originally aimed to sell 5.8 million shares.
ORK, Dec 21 (Reuters) - NUCRYST Pharmaceuticals Corp., a wholly owned subsidiary of Westaim Corp. ,on Wednesday priced the initial public offering of 4.5 million shares at $10 per share, below a forecast of $12 to $14.